# JointechLabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jointechlabs

- Industry: Healthcare Specialists
- Headquarters: San Francisco, US
- Website: www.jointechlabs.com
- Latest round: Seed (Nov 24, 2017)
- Investors on record: 1

## About

JointechLabs, Inc. is a pioneering company specializing in point-of-care regenerative medicine therapies, offering innovative solutions for various medical applications.Founded in 2012 in San Francisco, US, JointechLabs, Inc. focuses on regenerative medicine. The company was established by Nathan Katz and Nishit Pancholi, with Katz currently serving as CEO. JointechLabs raised seed funding in November 2017, marking a significant milestone in its investment journey.Jointechlabs specializes in point-of-care regenerative medicine therapies, primarily through their flagship products, the MiniTC® and Mini-Stem System®. The MiniTC® device processes autologous fat (adipose tissue) into purified microfat, which is utilized in various therapeutic applications including pain management, orthopedics, sports medicine, aesthetics, reconstruction, and wound healing. The Mini-Stem System® is designed for the processing of stromal vascular fraction (SVF) outside of the USA and has obtained CE-Mark approval. The company serves a clientele that includes cosmetic doctors, orthopedic surgeons, and clinics focused on regenerative medicine throughout international markets, making significant inroads in regions such as Europe and beyond. Jointechlabs emphasizes the advantages of microfat over synthetic products, promoting better healing outcomes, reduced complications, and enhanced patient satisfaction.Jointechlabs operates on a direct-to-consumer model, providing its innovative products to medical professionals and clinics involved in regenerative therapies. The company's transactions are structured around the sale of its proprietary devices and systems, with a focus on partnerships with healthcare providers who utilize the MiniTC® and Mini-Stem System® in their practices. Revenue generation occurs through the sale of these flagship products, which are priced to reflect their advanced technology and regulatory compliance. Given the medical nature of these products, pricing structures typically involve bulk purchases or contracts with healthcare institutions, enabling doctors and clinics to incorporate these regenerative therapies into their treatment offerings effectively. The company's commitment to quality and adherence to regulatory standards further supports its market presence and revenue potential.JointechLabs, Inc. is focused on expanding its product line and market reach. Plans include the launch of new devices aimed at enhancing therapeutic applications in the near future. The company also seeks to penetrate additional international markets, particularly in Europe, by 2025. The recent seed funding raised in November 2017 will support these initiatives, enabling the company to accelerate product development and expand its distribution network.

## Funding rounds

- Seed, Nov 24, 2017 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed